Moderna's COVID-19 vaccine OK'd in Canada for children aged 6 months and older
Moderna Inc. said Thursday its COVID-19 vaccine Spikevax was approved by Health Canada for use in children aged six months to five years. The biotechnology company said the two-dose regimen for children in that age group is completed in one month, the same as for adults, adolescents and children over five years old. Moderna's vaccine was authorized in the U.S. last month for use in that age group. Moderna's stock, which slumped 5.1% in midday trading, has slipped 1.8% over the past three months, while the iShares Biotechnology ETF has lost 7.1% and the S&P 500 has dropped 14.3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.